Fk 506 and Autoimmune Disease: Perspective and Prospects

Thomson, Angus W.; Starzl, Thomas E.

doi:10.3109/08916939209148473

Cited by 23 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…particularly in liver transplantation, and may prove superior to CyA" by virtue of successfully reversing acute ongoing liver rejection [12,13]. Currently its potential value in the treatment of T-celldependent autoimmune conditions such as uveitis, nephrotic syndrome, and also psoriasis is being evaluated [14]. In contrast, clinical trials with RPM have only recently begun following its efFectivej suppression of experimental organ rejection and autoimmune diseases [8,15,16].…”

mentioning

confidence: 98%

Differential Inhibition of Cutaneous T-Cell-Mediated Reactions and Epidermal Cell Proliferation by Cyclosporin A, FK-506, and Rapamycin

Duncan

1994

Journal of Investigative Dermatology

View full text Add to dashboard Cite

mentioning

confidence: 98%

Differential Inhibition of Cutaneous T-Cell-Mediated Reactions and Epidermal Cell Proliferation by Cyclosporin A, FK-506, and Rapamycin

Duncan

1994

Journal of Investigative Dermatology

View full text Add to dashboard Cite

“…In man, FK 506 is effective in the prevention and reversal of liver, heart and kidney allograft rejection [15], in permitting the long-term survival of small bowel allografts [16] and in sup- pressing rejection of transplanted pancreatic islets [17]. Early experience also indicates that it is effective in treatment of psoriasis, nephrotic syndrome, uveitis and pyoderma gangrenosum [15,18]. Although, like CsA, FK 506 is potentially nephrotoxic, its range of side effects is more restricted than that of CsA.…”

mentioning

confidence: 99%

The spectrum of action of new immunosuppressive drugs

Thomson

1992

Clinical and Experimental Immunology

View full text Add to dashboard Cite

“…uveitis [II], lupus disease [12] and experimental allergic encephalomyelitis [13[. Preliminary data have also revealed the cflieacy and safety of FK 506 in certain human autoimmune diseases, including psoriasis, nephrotic syndrome and uveitis [14].…”

Section: Introductionmentioning

confidence: 99%

Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production

Tamura

Woo

Murase

et al. 1993

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Autoimmune thyroid disease was induced in female PVG/c rats by neonatal thymectomy, followed by sublethal, whole body x-irradiation. Disease development, assessed by histological evidence of lymphocytic thyroiditis and circulating levels of anti-thyroglobulin antibodies, was reduced significantly by a 3-week course of FK 506 (0.5 or 1.5 mg/kg per day) commencing after the detection of autoantibody production. Thyroid-infiltrating mononuclear cells (MNC) in untreated rats stained predominantly for CD4+ and MHC class II antigen which was expressed widely on dendritic cells. Fewer infiltrating cells expressed TCR alpha/beta, CD5, CD8 or LFA-1 beta. Intercellular adhesion molecule-1 (ICAM-1) was observed on MNC, vascular endothelial cells and a minority of residual thyroid epithelial cells. FK 506 administration reduced markedly the incidence of infiltrating TCR alpha/beta +, CD5+, CD4+, CD8+, and LFA-1 beta + cells and the expression both of MHC class II antigens and ICAM-1 on MNC, endothelial cells and thyrocytes. Compared with normal PVG/c rats, there were reduced incidences of CD4+ CD8- and CD4- CD8+ lymphocytes and an elevation in the CD4+/CD8+ cell ratio in the spleens of animals with autoimmune thyroiditis. These changes were partially reversed by FK 506. Systemic drug levels estimated by enzyme immunosorbent assay were in excess of those known to blockade cytokine production by CD4+ T lymphocytes in vitro and some evidence of minor renal dysfunction was observed. The results are consistent with a therapeutic effect of FK 506 mediated via interference with CD4+ T lymphocyte function and adhesion molecule-dependent cytotoxic effector mechanisms.

show abstract

Fk 506 and Autoimmune Disease: Perspective and Prospects

Cited by 23 publications

References 37 publications

Differential Inhibition of Cutaneous T-Cell-Mediated Reactions and Epidermal Cell Proliferation by Cyclosporin A, FK-506, and Rapamycin

Differential Inhibition of Cutaneous T-Cell-Mediated Reactions and Epidermal Cell Proliferation by Cyclosporin A, FK-506, and Rapamycin

The spectrum of action of new immunosuppressive drugs

Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production

Contact Info

Product

Resources

About